Key result
Beta blockers are supported as a critical component of standard therapy for chronic heart failure with systolic left ventricular dysfunction based on major clinical trials.
Why the study?
Do beta blocking agents improve outcomes in heart failure populations with systolic left ventricular dysfunction?
Population
Heart failure populations with systolic left ventricular dysfunction
Design
Review
Authors
Loading...
Supports beta-blocker use in systolic HF; leaves open optimal agent selection and dosing in contemporary populations.
Do beta blocking agents improve outcomes in heart failure populations with systolic left ventricular dysfunction?
This review highlights the paradigm shift and evidence supporting beta-blockers as a critical component of standard therapy for chronic heart failure with systolic dysfunction.
Denise D. Hermann (2002) conducted a review in Chronic heart failure with systolic left ventricular dysfunction. Beta blockers was evaluated. Beta blockers are supported as a critical component of standard therapy for chronic heart failure with systolic left ventricular dysfunction based on major clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: